nach oben

Current Hypertension Reports

Erschienen in:

01.01.2014 | Hypertension and Metabolic Syndrome (J Sowers and A Whaley-Connell, Section Editors)

Membrane Estrogen Receptors: Their Role in Blood Pressure Regulation and Cardiovascular Disease

verfasst von: Roopashree Prabhushankar, Caroline Krueger, Camila Manrique

Erschienen in: Current Hypertension Reports | Ausgabe 1/2014

Einloggen, um Zugang zu erhalten

Abstract

Hypertension (HTN) is a leading risk factor for cardiovascular disease (CVD) and continues to affect millions of people in industrialized nations. The increasing prevalence of HTN is closely related to the growing prevalence of obesity. Despite heightened awareness of the disease, a significant percentage of patients are uncontrolled and are at higher risk of heart failure, stroke, and chronic kidney disease. Evidence of the cardiovascular protective role of estrogen in pre-menopausal females has brought attention to estrogen receptor activation as a treatment strategy for HTN. Estrogen promotes vasodilation and decreases inflammation and atherosclerosis. It also controls blood pressure via modulation of the activity of the renin-angiotensin-aldosterone system. The effects of estrogen on the vasculature are partly mediated via membrane receptors. Membrane estrogen receptor α and G-protein-coupled GPER-1 have been studied extensively in the vasculature. This review will describe the available evidence supporting the role of estrogen membrane receptors in blood pressure control and CVD.

Roger VL, Go AS, Lloyd-Jones DM, Benjamin EJ. Heart disease and stroke statistics–2012 update: a report from the American Heart Association. Circulation. 2012;125(1):e2–220. doi:10.1161/CIR.0b013e31823ac046.PubMedCrossRef

Heidenreich PA, Trogdon JG, Khavjou OA, Butler J, Dracup K. Forecasting the future of cardiovascular disease in the United States: a policy statement from the American Heart Association. Circulation. 2011;123(8):933–44. doi:10.1161/CIR.0b013e31820a55f5.PubMedCrossRef

Ostchega Y, Yoon SS, Hughes J, Louis T. Hypertension awareness, treatment, and control – continued disparities in adults: United States, 2005–2006. NCHS Data Brief No. 3. Hyattsville, MD: National Center for Health Statistics. 2008. MMWR. 2011;60(4):103–8.

Landsberg L, Aronne LJ, Beilin LJ, Burke V, Igel LI, Lloyd-Jones D, et al. Obesity-related hypertension: pathogenesis, cardiovascular risk, and treatment–a position paper of the The Obesity Society and The American Society of Hypertension. Obesity (Silver Spring). 2013;21(1):8–24. doi:10.1002/oby.20181.CrossRef

Muniyappa R, Sowers JR. Role of insulin resistance in endothelial dysfunction. Rev Endocr Metab Disord. 2013;14:5–12. doi:10.1007/s11154-012-9229-1.PubMedCrossRef

6.•

Sandberg K, Ji H. Sex differences in primary hypertension. Biol Sex Differ. 2012;3:7. doi:10.1186/2042-6410-3-7. Comprehensive review of the biological differences in blood pressure both in animal models and in humans.PubMedCentralPubMedCrossRef

Blood pressure studies in 14 communities. A two-stage screen for hypertension. JAMA. 1977;237:2385–91.CrossRef

8.•

Murphy E. Estrogen signaling and cardiovascular disease. Circ Res. 2011;109:687–96. doi:10.1161/CIRCRESAHA.110.236687. Author reviews the available evidence of estrogen action in the vasculature.PubMedCentralPubMedCrossRef

Barton M. Position paper: The membrane estrogen receptor GPER–Clues and questions. Steroids. 2012;77:935–42. doi:10.1016/j.steroids.2012.04.001.PubMedCrossRef

10.

Greene GL, Gilna P, Waterfield M, Baker A, Hort Y, Shine J. Sequence and expression of human estrogen receptor complementary DNA. Science. 1986;231:1150–4.PubMedCrossRef

11.

Korenman SG. Comparative binding affinity of estrogens and its relation to estrogenic potency. Steroids. 1969;13:163–77.PubMedCrossRef

12.

Kuiper GG, Enmark E, Pelto-Huikko M, Nilsson S, Gustafsson JA. Cloning of a novel receptor expressed in rat prostate and ovary. Proc Natl Acad Sci U S A. 1996;93:5925–30.PubMedCentralPubMedCrossRef

13.

Dechering K, Boersma C, Mosselman S. Estrogen receptors alpha and beta: two receptors of a kind? Curr Med Chem. 2000;7:561–76.PubMedCrossRef

14.

Kuiper GG, Carlsson B, Grandien K, Enmark E, Haggblad J, Nilsson S, et al. Comparison of the ligand binding specificity and transcript tissue distribution of estrogen receptors alpha and beta. Endocrinology. 1997;138:863–70.PubMed

15.

Hall JM, Couse JF, Korach KS. The multifaceted mechanisms of estradiol and estrogen receptor signaling. J Biol Chem. 2001;276:36869–72.PubMedCrossRef

16.

Giannattasio C, Failla M, Grappiolo A, Stella ML, Del Bo A, Colombo M, et al. Fluctuations of radial artery distensibility throughout the menstrual cycle. Arterioscler Thromb Vasc Biol. 1999;19:1925–9.PubMedCrossRef

17.

Wu Q, Chambliss K, Umetani M, Mineo C, Shaul PW. Non-nuclear estrogen receptor signaling in the endothelium. J Biol Chem. 2011;286:14737–43. doi:10.1074/jbc.R110.191791.PubMedCrossRef

18.

Pietras RJ, Szego CM. Specific binding sites for oestrogen at the outer surfaces of isolated endometrial cells. Nature. 1977;265:69–72.PubMedCrossRef

19.

Filardo EJ, Quinn JA, Bland KI, Frackelton Jr AR. Estrogen-induced activation of Erk-1 and Erk-2 requires the G protein-coupled receptor homolog, GPR30, and occurs via trans-activation of the epidermal growth factor receptor through release of HB-EGF. Mol Endocrinol. 2000;14:1649–60.PubMed

20.

Thomas P, Pang Y, Filardo EJ, Dong J. Identity of an estrogen membrane receptor coupled to a G protein in human breast cancer cells. Endocrinology. 2005;146:624–32.PubMedCrossRef

21.

Revankar CM, Cimino DF, Sklar LA, Arterburn JB, Prossnitz ER. A transmembrane intracellular estrogen receptor mediates rapid cell signaling. Science. 2005;307:1625–30.PubMedCrossRef

22.

Haas E, Meyer MR, Schurr U, Bhattacharya I, Minotti R, Nguyen HH, et al. Differential effects of 17beta-estradiol on function and expression of estrogen receptor alpha, estrogen receptor beta, and GPR30 in arteries and veins of patients with atherosclerosis. Hypertension. 2007;49:1358–63.PubMedCrossRef

23.

Bologa CG, Revankar CM, Young SM, Edwards BS, Arterburn JB, Kiselyov AS, et al. Virtual and biomolecular screening converge on a selective agonist for GPR30. Nat Chem Biol. 2006;2:207–12.PubMedCrossRef

24.

Meyer MR, Baretella O, Prossnitz ER, Barton M. Dilation of epicardial coronary arteries by the G protein-coupled estrogen receptor agonists G-1 and ICI 182,780. Pharmacology. 2010;86:58–64. doi:10.1159/000315497.PubMedCrossRef

25.

Broughton BR, Miller AA, Sobey CG. Endothelium-dependent relaxation by G protein-coupled receptor 30 agonists in rat carotid arteries. Am J Physiol Heart Circ Physiol. 2010;298:H1055–61. doi:10.1152/ajpheart.00878.2009.PubMedCrossRef

26.••

Haas E, Bhattacharya I, Brailoiu E, Damjanović M, et al. Regulatory role of G protein–coupled estrogen receptor for vascular function and obesity. Circ Res. 2009;104:288–91. doi:10.1161/CIRCRESAHA.108.190892. Authors explore role of GPER-1 in isolated VSMC. First description of the GPER-1 knockout rodent.PubMedCentralPubMedCrossRef

27.

Mårtensson UE, Salehi SA, Windahl S, Gomez MF, et al. Deletion of the G protein-coupled receptor 30 impairs glucose tolerance, reduces bone growth, increases blood pressure, and eliminates estradiol-stimulated insulin release in female mice. Endocrinology. 2009;150:687–98. doi:10.1210/en.2008-0623.PubMedCrossRef

28.

Meyer MR, Amann K, Field AS, et al. Deletion of G protein–coupled estrogen receptor increases endothelial vasoconstriction. Hypertension. 2012;59:507–12. doi:10.1161/HYPERTENSIONAHA.111.184606.PubMedCentralPubMedCrossRef

29.••

Lindsey SH, da Silva AS, Silva MS, Chappell MC. Reduced vasorelaxation to estradiol and G-1 in aged female and adult male rats is associated with GPR30 downregulation. Am J Physiol Endocrinol Metab. 2013;305:E113–8. doi:10.1152/ajpendo.00649.2012. Authors explore the effect of G1 agonists in male and female rats, as well as estradiol signaling via GPER-1.PubMedCrossRef

30.

Lindsey SH, Cohen JA, Brosnihan KB, Gallagher PE, Chappell MC. Chronic treatment with the G protein-coupled receptor 30 agonist G-1 decreases blood pressure in ovariectomized mRen2.Lewis rats. Endocrinology. 2009;150:3753–8.PubMedCrossRef

31.

Lindsey SH, Carver KA, Prossnitz ER, Chappell MC. Vasodilation in response to the GPR30 agonist G-1 is not different from estradiol in the mRen2.Lewis female rat. J Cardiovasc Pharmacol. 2011;57:598–603.PubMedCentralPubMedCrossRef

32.

Ding Q, Gros R, Limbird LE, Chorazyczewski J, Feldman RD. Estradiol-mediated ERK phosphorylation and apoptosis in vascular smooth muscle cells requires GPR 30. Am J Physiol Cell Physiol. 2009;297:C1178–87. doi:10.1152/ajpcell.00185.2009.PubMedCrossRef

33.

Bender SB, McGraw AP, Jaffe IZ, Sowers JR. Mineralocorticoid receptor–mediated vascular insulin resistance: an early contributor to diabetes-related vascular disease? Diabetes. 2013;62:313–9. doi:10.2337/db12-0905.PubMedCrossRef

34.••

Gros R, Ding Q, Sklar LA, et al. GPR30 expression is required for the mineralocorticoid receptor–independent rapid vascular effects of aldosterone. Hypertension. 2011;57:442–51. doi:10.1161/HYPERTENSIONAHA.110.161653. Interesting article demonstrating signaling of aldosterone via GPER-1.PubMedCrossRef

35.

Gros R, Ding Q, Liu B, Chorazyczewski J, Feldman RD. Aldosterone mediates its rapid effects in vascular endothelial cells through GPER activation. Am J Physiol Cell Physiol. 2013;304:C532–40. doi:10.1152/ajpcell.00203.2012.PubMedCrossRef

36.

Deschamps AM, Murphy E. Activation of a novel estrogen receptor, GPER, is cardioprotective in male and female rats. Am J Physiol Heart Circ Physiol. 2009;297:H1806–13. doi:10.1152/ajpheart.00283.2009.PubMedCrossRef

37.

Jessup JA, Lindsey SH, Wang H, Chappell MC, Groban L. Attenuation of salt-induced cardiac remodeling and diastolic dysfunction by the GPER agonist G-1 in female mRen2.Lewis rats. PLoS ONE. 2010;5:e15433.PubMedCentralPubMedCrossRef

38.

Garrido P, Moran J, Alonso A, Gonzalez S, Gonzalez C. 17β-estradiol activates glucose uptake via GLUT4 translocation and PI3K/Akt signaling pathway in MCF-7 cells. Endocrinology. 2013;154:1979–89. doi:10.1210/en.2012-1558.PubMedCrossRef

39.

Chen Z, Yuhanna IS, Galcheva-Gargova Z, et al. Estrogen receptor α mediates the nongenomic activation of endothelial nitric oxide synthase by estrogen. J Clin Invest. 1999;103:1363. doi:10.1172/JCI5347E1.CrossRef

40.••

Chambliss KL, Wu Q, Oltmann S, et al. Non-nuclear estrogen receptor alpha signaling promotes cardiovascular protection but not uterine or breast cancer growth in mice. J Clin Invest. 2010;120(7):2319–30. doi:10.1172/JCI38291. Authors elegantly explore the beneficial vascular effects of membrane estrogen receptor alpha agonism with a new compound without proliferative effects in mammary gland or uterus.PubMedCentralPubMedCrossRef

41.

Pedram A, Razandi M, Levin ER. Nature of functional estrogen receptors at the plasma membrane. Mol Endocrinol. 2006;20:1996–2009.PubMedCrossRef

42.

Cooper SA, Whaley-Connell A, Habibi J, et al. Renin-angiotensin-aldosterone system and oxidative stress in cardiovascular insulin resistance. Am J Physiol Heart Circ Physiol. 2007;293:H2009–23.PubMedCrossRef

43.

Xue B, Pamidimukkala J, Lubahn DB, Hay M. Estrogen receptor-alpha mediates estrogen protection from angiotensin II-induced hypertension in conscious female mice. Am J Physiol Heart Circ Physiol. 2007;292:H1770–6.PubMedCrossRef

44.

Xue B, Badaue-Passos Jr D, Guo F, Gomez-Sanchez CE, Hay M, Johnson AK. Sex differences and central protective effect of 17beta-estradiol in the development of aldosterone/NaCl-induced hypertension. Am J Physiol Heart Circ Physiol. 2009;296:H1577–85. doi:10.1152/ajpheart.01255.2008.PubMedCrossRef

45.

Zhu Y, Bian Z, Lu P, et al. Abnormal vascular function and hypertension in mice deficient in estrogen receptor beta. Science. 2002;295:505–8.PubMedCrossRef

46.

Xue B, Zhang Z, Beltz TG, et al. Estrogen receptor-β in the paraventricular nucleus and rostroventrolateral medulla plays an essential protective role in aldosterone/salt-induced hypertension in female rats. Hypertension. 2013;61:1255–62. doi:10.1161/HYPERTENSIONAHA.111.00903.PubMedCrossRef

Titel: Membrane Estrogen Receptors: Their Role in Blood Pressure Regulation and Cardiovascular Disease
verfasst von: Roopashree Prabhushankar
Caroline Krueger
Camila Manrique
Publikationsdatum: 01.01.2014
Verlag: Springer US
Erschienen in: Current Hypertension Reports / Ausgabe 1/2014
Print ISSN: 1522-6417
Elektronische ISSN: 1534-3111
DOI: https://doi.org/10.1007/s11906-013-0408-6

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

„Jeder Fall von plötzlichem Tod muss obduziert werden!“

17.05.2024 Plötzlicher Herztod Nachrichten

Ein signifikanter Anteil der Fälle von plötzlichem Herztod ist genetisch bedingt. Um ihre Verwandten vor diesem Schicksal zu bewahren, sollten jüngere Personen, die plötzlich unerwartet versterben, ausnahmslos einer Autopsie unterzogen werden.

Hirnblutung unter DOAK und VKA ähnlich bedrohlich

17.05.2024 Direkte orale Antikoagulanzien Nachrichten

Kommt es zu einer nichttraumatischen Hirnblutung, spielt es keine große Rolle, ob die Betroffenen zuvor direkt wirksame orale Antikoagulanzien oder Marcumar bekommen haben: Die Prognose ist ähnlich schlecht.

Schlechtere Vorhofflimmern-Prognose bei kleinem linken Ventrikel

17.05.2024 Vorhofflimmern Nachrichten

Nicht nur ein vergrößerter, sondern auch ein kleiner linker Ventrikel ist bei Vorhofflimmern mit einer erhöhten Komplikationsrate assoziiert. Der Zusammenhang besteht nach Daten aus China unabhängig von anderen Risikofaktoren.

Semaglutid bei Herzinsuffizienz: Wie erklärt sich die Wirksamkeit?

17.05.2024 Herzinsuffizienz Nachrichten

Bei adipösen Patienten mit Herzinsuffizienz des HFpEF-Phänotyps ist Semaglutid von symptomatischem Nutzen. Resultiert dieser Benefit allein aus der Gewichtsreduktion oder auch aus spezifischen Effekten auf die Herzinsuffizienz-Pathogenese? Eine neue Analyse gibt Aufschluss.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen